Powered by 2021 is off to a strong start in terms of psychedelics research, with plenty of insightful papers published in January. An RCT of repeated ketamine administration for PTSD found that, among those who responded to the drug, the median time to loss of response was less than a month (27.5 days). Ketamine was also studied in the context of treatment-resistant depression (TRD).


Previous articlePsyCap Recap: 3 Key Takeaways From the January 2021 Mindset Pharma Psychedelic Capital Presentation
Next articleWhat Is Peyote? Everything You Need to Know About Mescaline Cactus